^
Association details:
Biomarker:No biomarker
Cancer:Prolymphocytic Leukemia
Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/21/2023
Excerpt:
T-Cell Prolymphocytic Leukemia: SUGGESTED TREATMENT REGIMENS...Ruxolitinib…